Perphenazine (Trilafon) Veterinary Grade API is a 2-chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine supplied as a non-sterile active pharmaceutical ingredient for further manufacture into tablets, injections, capsules, powders, granules, premixes, and solutions. The molecular formula C21H26ClN3OS corresponds to a mean molecular weight of 403.97 g/mol; the CAS registry number is 58-39-9. The free base is a white to off-white crystalline powder that is practically insoluble in water and soluble in selected organic solvents; protonation of the piperazinyl nitrogen permits acidified aqueous solution manufacture. The designation “Trilafon” is retained as an originator brand reference; the veterinary-grade API is not the finished human branded tablet and is supplied only for registered veterinary medicinal product manufacture or extemporaneous compounding under veterinary oversight in jurisdictions where such use is lawful. Release documentation aligns with ICH Q3D for elemental impurities and USP <467> for residual solvents when applicable. The drug substance is handled under current good manufacturing practice regulations for veterinary APIs; for feed premix operations, feed CGMP under 21 CFR 225.1 applies when the API is incorporated into medicated feed intermediates. The API should not be mixed with strong oxidizing agents, and exposure to direct sunlight during open handling is avoided because the phenothiazine sulfur atom undergoes photooxidation.

How Does the Piperazinylphenothiazine Core Influence Milling and Blending?

Compared with chlorpromazine, which has an N,N-dimethylaminopropyl side chain, perphenazine carries a 4-(2-hydroxyethyl)piperazin-1-ylpropyl side chain. The terminal 2-hydroxyethyl group increases polarity and hydrogen-bonding potential relative to the methyl-substituted prochlorperazine; this influences wet granulation, in which cellulosic binders such as hypromellose or pregelatinized starch interact more readily with the API surface. The free base remains practically insoluble in water, but acidification below the piperazine pKa produces the water-soluble protonated species needed for sterile solution manufacture. If the pH is raised too early during formulation, the free base crystallizes and can occlude sterilizing-grade filter membranes. Pilot-scale observations indicate that slow addition into a chilled acidified vehicle at 4–15°C under a nitrogen headspace reduces localized supersaturation and color formation. Milling and blending are conducted under low-intensity yellow light to limit photolytic oxidation. Air-jet micronization at 0.2–0.8 MPa nozzle pressure is used for injection-grade material; production-scale hammer milling at a classifier speed of 3,000–6,000 rpm is used for oral-grade particle reduction. Particle size distribution is confirmed by laser diffraction per ISO 13320:2020 after each milling campaign, because the milled API tends to agglomerate if residual surface moisture exceeds 3% w/w.

Among these derivatives, perphenazine combines 2-chloro substitution with a terminal 2-hydroxyethyl piperazine, producing a distinct balance between hydrogen-bonding capacity and lipophilicity. That balance directly affects granulation liquid demand, capsule fill retention, and the choice of wet-massing time in high-shear granulation.

Acceptance Parameters for Veterinary-Scale Batch Release

Release criteria are set to compendial standards and are confirmed on each lot by qualified HPLC and pharmacopeial methods. The specification below represents the standard non-sterile veterinary API profile; sterility assurance and endotoxin limits for injection manufacture are applied to the finished sterile product rather than the unsterilized API. If the downstream product is labeled sterile, the active substance must pass bacterial endotoxin testing at the finished-product stage because the API itself is not supplied as a sterile substance.

When Dry Granulation Replaces Aqueous Granulation in Low-Dose Tablet Manufacture

Tablet manufacture with perphenazine at active fractions below 5% w/w can be carried out by direct compression when the API and excipients are matched by particle size. A twin-shell blender operated at 15–20 rpm for 20 min is a common starting point; blend uniformity is confirmed by stratified sampling and assay per USP <905>. Overblending can increase electrostatic adhesion to the blender walls and reduce flow through the tablet press feed frame. Roller compaction is used when the API has a D90 above 100 µm or when a higher bulk density is required for automatic capsule filling. Granules are compacted at 0.8–1.2 mm screen aperture after briquetting. Compression force is adjusted to produce tablets with hardness of 30–70 N and friability below 1% per USP <1216>. Disintegration is tested in 0.1 M hydrochloric acid at 37°C; dissolution is performed under USP <711> with paddle speed 50 rpm. The optimum relative humidity during compression is 40–55%; higher humidity increases sticking to upper punches when lubrication is insufficient. Sodium stearyl fumarate at 1–2% w/w is preferred over magnesium stearate when the formulation is exposed to moisture because it reduces over-lubrication. If aqueous granulation is elected, the granulating fluid should be acidified for drug substance solubility, but the terminal hydroxyl group increases tackiness; a high-shear granulator with an impeller speed of 100–200 rpm and a chopper speed of 1,000–1,500 rpm is used for wet massing times of 2–4 min to avoid uncontrolled particle growth. Drying is performed in a fluid-bed dryer with an inlet air temperature of 50–60°C and an exhaust air temperature not exceeding 40°C.

The un-milled API is supplied in double low-density polyethylene liners inside an HDPE drum with tamper-evident seal; the liner is flushed with nitrogen before sealing and the unit is stored at 15–25°C in a dry, light-protected warehouse. Under these conditions, re-test dating is typically assigned at 24–36 months from release when supported by stability data generated per ICH Q1A. Re-packaging into smaller aliquots should be performed under amber light and at 35–45% relative humidity; prolonged exposure to open air should be avoided because the powder can gain surface moisture and shift particle size distribution. Aqueous granulation slurries should not be held for more than 6 h at room temperature unless a stability-indicating assay has shown acceptable degradation; the phenothiazine chromophore can oxidize to a discolored sulfoxide impurity in the presence of trace metals and dissolved oxygen. Chelating agents such as edetate disodium at 0.01–0.1% w/w are used in solution formulations to minimize metal-catalyzed oxidation.

Solution dosage forms are prepared by dissolving perphenazine free base in an acidified aqueous vehicle under nitrogen sparging. A 0.22 µm PVDF membrane is used for aseptic filtration after pH adjustment; terminal autoclaving is generally avoided because the free base precipitates at neutral pH and the phenothiazine ring can undergo hydrolytic and oxidative discoloration. Filter compatibility is checked with a small-scale pressure hold test; polyether sulfone membranes may exhibit nonspecific binding at low concentrations, but published data for this specific veterinary configuration is limited. Amber type I glass vials with a headspace oxygen content below 2% limit photolytic degradation; stability-indicating testing is conducted under ICH Q1B photostability conditions. Injectable preparations should not be mixed with strong bases, and the pH should be maintained in the acidified range during filling to prevent recrystallization.

Capsule manufacture typically uses low-shear tumble mixing with pregelatinized starch and lactose monohydrate, followed by encapsulation at 20–25°C and 35–45% relative humidity to prevent static charge and slug formation. Powder and granule intermediates are packaged in aluminum-laminate sachets with desiccant; moisture gain above 5% w/w can alter particle flow and content uniformity. For feed premix manufacture, the API is first geometrically diluted to a 0.1–1.0% active premix before final feed dilution onto calcium carbonate, corn cob or wheat middlings carriers. Homogeneity is confirmed by assay of 10 stratified samples per USP <905>; carrier particles retained on a 500 µm sieve should be matched to the API-loaded fraction to reduce segregation during pneumatic transfer.

For oral solutions, citrate or tartrate buffers at pH 4.0–4.5 maintain the protonated form; glass or high-density polyethylene containers lined with amber colorant are used. The solution should be protected from light during storage and administration line filling. Published stability data for certain flavored veterinary palatability systems is limited; therefore, a formal stability study per ICH Q1A should be generated for each finished formula. The API is not intended for direct administration without a qualified manufacturing step, and final veterinary dose forms must be prepared under veterinary oversight in compliance with applicable regional regulations.